ESRRA and breast carcinoma: In summary, the purpose of our study was to explore a novel regulatory mechanism of ERRα serving as a transcription factor to activate the transcription of SHMT2 and to affect ER- and HER2-positive breast cancer cell resistance to lapatinib.